Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases
Overall Portfolio Of 11 Products Includes Three From Two Unnamed Firms
Following on from its initial 2019 alliance, Israel’s Kamada has added a further two biosimilar products to its local distribution agreement with Alvotech. The firm’s CEO discussed its planned foray into the biosimilar space as part of a letter to shareholders.
You may also be interested in...
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.